Systems immunology reveals a linked IgG3–C4 response in patients with acute rheumatic fever
Amy W Chung
Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia
Search for more papers by this authorTimothy KC Ho
School of Medical Sciences, University of Auckland, Auckland, New Zealand
Search for more papers by this authorPaulina Hanson-Manful
School of Medical Sciences, University of Auckland, Auckland, New Zealand
Maurice Wilkins Centre for Biodiscovery, University of Auckland, Auckland, New Zealand
Search for more papers by this authorSusanne Tritscheller
School of Medical Sciences, University of Auckland, Auckland, New Zealand
Search for more papers by this authorJeremy M Raynes
School of Medical Sciences, University of Auckland, Auckland, New Zealand
Maurice Wilkins Centre for Biodiscovery, University of Auckland, Auckland, New Zealand
Search for more papers by this authorAlana L Whitcombe
School of Medical Sciences, University of Auckland, Auckland, New Zealand
Maurice Wilkins Centre for Biodiscovery, University of Auckland, Auckland, New Zealand
Search for more papers by this authorMei Lin Tay
School of Medical Sciences, University of Auckland, Auckland, New Zealand
Maurice Wilkins Centre for Biodiscovery, University of Auckland, Auckland, New Zealand
Search for more papers by this authorReuben McGregor
School of Medical Sciences, University of Auckland, Auckland, New Zealand
Maurice Wilkins Centre for Biodiscovery, University of Auckland, Auckland, New Zealand
Search for more papers by this authorNatalie Lorenz
School of Medical Sciences, University of Auckland, Auckland, New Zealand
Maurice Wilkins Centre for Biodiscovery, University of Auckland, Auckland, New Zealand
Search for more papers by this authorJane R Oliver
Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia
University of Otago, Wellington, New Zealand
Search for more papers by this authorCristin G Print
School of Medical Sciences, University of Auckland, Auckland, New Zealand
Maurice Wilkins Centre for Biodiscovery, University of Auckland, Auckland, New Zealand
Search for more papers by this authorNigel J Wilson
Starship Children's Hospital, Auckland, New Zealand
Search for more papers by this authorWilliam J Martin
Science for Technological Innovation Science Challenge, Callaghan Innovation, Wellington, New Zealand
Search for more papers by this authorDeborah A Williamson
Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia
Search for more papers by this authorCorresponding Author
Nicole J Moreland
School of Medical Sciences, University of Auckland, Auckland, New Zealand
Maurice Wilkins Centre for Biodiscovery, University of Auckland, Auckland, New Zealand
Correspondence
Nicole J Moreland, School of Medical Sciences, University of Auckland, 85 Park Road, Grafton 1023, Auckland, New Zealand.
E-mail: [email protected]
Search for more papers by this authorAmy W Chung
Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia
Search for more papers by this authorTimothy KC Ho
School of Medical Sciences, University of Auckland, Auckland, New Zealand
Search for more papers by this authorPaulina Hanson-Manful
School of Medical Sciences, University of Auckland, Auckland, New Zealand
Maurice Wilkins Centre for Biodiscovery, University of Auckland, Auckland, New Zealand
Search for more papers by this authorSusanne Tritscheller
School of Medical Sciences, University of Auckland, Auckland, New Zealand
Search for more papers by this authorJeremy M Raynes
School of Medical Sciences, University of Auckland, Auckland, New Zealand
Maurice Wilkins Centre for Biodiscovery, University of Auckland, Auckland, New Zealand
Search for more papers by this authorAlana L Whitcombe
School of Medical Sciences, University of Auckland, Auckland, New Zealand
Maurice Wilkins Centre for Biodiscovery, University of Auckland, Auckland, New Zealand
Search for more papers by this authorMei Lin Tay
School of Medical Sciences, University of Auckland, Auckland, New Zealand
Maurice Wilkins Centre for Biodiscovery, University of Auckland, Auckland, New Zealand
Search for more papers by this authorReuben McGregor
School of Medical Sciences, University of Auckland, Auckland, New Zealand
Maurice Wilkins Centre for Biodiscovery, University of Auckland, Auckland, New Zealand
Search for more papers by this authorNatalie Lorenz
School of Medical Sciences, University of Auckland, Auckland, New Zealand
Maurice Wilkins Centre for Biodiscovery, University of Auckland, Auckland, New Zealand
Search for more papers by this authorJane R Oliver
Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia
University of Otago, Wellington, New Zealand
Search for more papers by this authorCristin G Print
School of Medical Sciences, University of Auckland, Auckland, New Zealand
Maurice Wilkins Centre for Biodiscovery, University of Auckland, Auckland, New Zealand
Search for more papers by this authorNigel J Wilson
Starship Children's Hospital, Auckland, New Zealand
Search for more papers by this authorWilliam J Martin
Science for Technological Innovation Science Challenge, Callaghan Innovation, Wellington, New Zealand
Search for more papers by this authorDeborah A Williamson
Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia
Search for more papers by this authorCorresponding Author
Nicole J Moreland
School of Medical Sciences, University of Auckland, Auckland, New Zealand
Maurice Wilkins Centre for Biodiscovery, University of Auckland, Auckland, New Zealand
Correspondence
Nicole J Moreland, School of Medical Sciences, University of Auckland, 85 Park Road, Grafton 1023, Auckland, New Zealand.
E-mail: [email protected]
Search for more papers by this authorAbstract
Acute rheumatic fever (ARF) and chronic rheumatic heart disease (RHD) are autoimmune sequelae of a Group A streptococcal infection with significant global mortality and poorly understood pathogenesis. Immunoglobulin and complement deposition were observed in ARF/RHD valve tissue over 50 years ago, yet contemporary investigations have been lacking. This study applied systems immunology to investigate the relationships between the complement system and immunoglobulin in ARF. Patients were stratified by C-reactive protein (CRP) concentration into high (≥10 μg mL−1) and low (<10 μg mL−1) groups to distinguish those with clinically significant inflammatory processes from those with abating inflammation. The circulating concentrations of 17 complement factors and six immunoglobulin isotypes and subclasses were measured in ARF patients and highly matched healthy controls using multiplex bead-based immunoassays. An integrative statistical approach combining feature selection and principal component analysis revealed a linked IgG3–C4 response in ARF patients with high CRP that was absent in controls. Strikingly, both IgG3 and C4 were elevated above clinical reference ranges, suggesting these features are a marker of ARF-associated inflammation. Humoral immunity in response to M protein, an antigen implicated in ARF pathogenesis, was completely polarized to IgG3 in the patient group. Furthermore, the anti-M-protein IgG3 response was correlated with circulating IgG3 concentration, highlighting a potential role for this potent immunoglobulin subclass in disease. In conclusion, a linked IgG3–C4 response appears important in the initial, inflammatory stage of ARF and may have immediate utility as a clinical biomarker given the lack of specific diagnostic tests currently available.
Video Short
Systems immunology reveals a linked IgG3–C4 response in patients with acute rheumatic fever
by Chung et al.
Supporting Information
Filename | Description |
---|---|
imcb12298-sup-0001-Supinfo.pdfPDF document, 2.2 MB |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1Carapetis JR, Beaton A, Cunningham MW, et al. Acute rheumatic fever and rheumatic heart disease. Nat Rev Dis Primers 2016; 1: 1–24.
- 2Carapetis JR, McDonald M, Wilson NJ. Acute rheumatic fever. Lancet 2005; 366: 155–168.
- 3Steer AC. Historical aspects of rheumatic fever. J Paediatr Child Health 2015; 51: 21–27.
- 4Watkins DA, Johnson CO, Colquhoun SM, et al. Global, regional, and national burden of rheumatic heart disease, 1990–2015. N Engl J Med 2017; 377: 713–722.
- 5Milne RJ, Lennon DR, Stewart JM, Vander Hoorn S, Scuffham PA. Incidence of acute rheumatic fever in New Zealand children and youth. J Paediatr Child Health 2012; 48: 685–691.
- 6Parnaby MG, Carapetis JR. Rheumatic fever in indigenous Australian children. J Paediatr Child Health 2010; 46: 527–533.
- 7Cunningham MW. Streptococcus and rheumatic fever. Curr Opin Rheumatol 2012; 24: 408–416.
- 8Tandon R, Sharma M, Chandrashekhar Y, Kotb M, Yacoub MH, Narula J. Revisiting the pathogenesis of rheumatic fever and carditis. Nat Rev Cardiol 2013; 10: 171–177.
- 9Cunningham MW. Rheumatic fever revisited. Nat Rev Cardiol 2014; 11: 123.
- 10Karthikeyan G, Guilherme L. Acute rheumatic fever. Lancet 2018; 392: 161–174.
- 11Kaplan MH, Bolande R, Rakita L, Blair J. Presence of bound immunoglobulins and complement in the myocardium in acute rheumatic fever. Association with cardiac failure. N Engl J Med 1964; 271: 637–645.
- 12Bongoni AK, Lanz J, Rieben R, Banz Y. Development of a bead-based multiplex assay for the simultaneous detection of porcine inflammation markers using xMAP technology. Cytometry A 2013; 83: 636–647.
- 13Lash GE, Pinto LA. Multiplex cytokine analysis technologies. Expert Rev Vaccines 2010; 9: 1231–1237.
- 14Kidd BA, Peters LA, Schadt EE, Dudley JT. Unifying immunology with informatics and multiscale biology. Nat Immunol 2014; 15: 118–127.
- 15Chung AW, Alter G. Systems serology: profiling vaccine induced humoral immunity against HIV. Retrovirology 2017; 14: 57.
- 16Nakaya HI, Pulendran B. Vaccinology in the era of high-throughput biology. Phil Trans R Soc B 2015;. https://doi.org/10.1086/650310.
- 17Atatoa-Carr P, Lennon D, Wilson N, New Zealand Rheumatic Fever Guidelines Writing Group. Rheumatic fever diagnosis, management, and secondary prevention: a New Zealand guideline. NZ Med J 2008; 121: 59–69.
- 18Kushner I, Antonelli MJ. What should we regard as an ‘elevated’ C-reactive protein level? Ann Intern Med 2015; 163: 326.
- 19Gurney JK, Stanley J, Baker MG, Wilson NJ, Sarfati D. Estimating the risk of acute rheumatic fever in New Zealand by age, ethnicity and deprivation. Epidemiol Infect 2016; 1–10.
- 20Chung AW, Kumar MP, Arnold KB, et al. Dissecting polyclonal vaccine-induced humoral immunity against HIV using systems serology. Cell 2015; 163: 988–998.
- 21Fischetti VA. Streptococcal M protein: molecular design and biological behavior. Clin Microbiol Rev 1989; 2: 285–314.
- 22Williamson DA, Smeesters PR, Steer AC, et al. M-protein analysis of Streptococcus pyogenes isolates associated with acute rheumatic fever in New Zealand. J Clin Microbiol 2015; 53: 3618–3620.
- 23Hanson-Manful P, Whitcombe AL, Young PG, et al. The novel Group A Streptococcus antigen SpnA combined with bead-based immunoassay technology improves streptococcal serology for the diagnosis of acute rheumatic fever. J Infect 2018; 76: 361–368.
- 24Bensi G, Mora M, Tuscano G, et al. Multi high-throughput approach for highly selective identification of vaccine candidates: the Group A Streptococcus case. Mol Cell Proteomics 2012; 11: M111.015693–M111.015693.
- 25Smeesters PR, McMillan DJ, Sriprakash KS. The streptococcal M protein: a highly versatile molecule. Trends Microbiol 2010; 18: 275–282.
- 26Frost HR, Laho D, Sanderson-Smith ML, et al. Immune cross-opsonization within emm clusters following group A Streptococcus skin infection: broadening the scope of type-specific immunity. Clin Infect Dis 2017; 65: 1523–1531.
- 27Damelang T, Rogerson SJ, Kent SJ, Chung AW. Role of IgG3 in infectious diseases. Trends Immunol 2019; 40: 197–211.
- 28Bhattacharya S, Reddy KS, Sundaram KR, et al. Differentiation of patients with rheumatic fever from those with inactive rheumatic heart disease using the artificial subcutaneous nodule test, myocardial reactive antibodies, serum immunoglobulin and serum complement levels. Int J Cardiol 1987; 14: 71–78.
- 29Svartman M, Potter EV, Poon-King T, Earle DP. Immunoglobulins and complement components in synovial fluid of patients with acute rheumatic fever. J Clin Invest 1975; 56: 111–117.
- 30Mukherjee S, Jagadeeshaprasad MG, Banerjee T, et al. Proteomic analysis of human plasma in chronic rheumatic mitral stenosis reveals proteins involved in the complement and coagulation cascade. Clin Proteomics 2014; 11: 35.
- 31Markanday A. Acute phase reactants in infections: evidence-based review and a guide for clinicians. Open Forum Infect Dis 2015; 2: ofv098.
- 32Kim ML, Martin WJ, Minigo G, et al. Dysregulated IL-1β-GM-CSF axis in acute rheumatic fever that is limited by hydroxychloroquine. Circulation 2018; 138: 2648–2661.
- 33Martin WJ, Steer AC, Smeesters PR, et al. Post-infectious group A streptococcal autoimmune syndromes and the heart. Autoimmun Rev 2015; 14: 710–725.
- 34Balasubramanian R, Marks SD. Post-infectious glomerulonephritis. Paediatr Int Child Health 2017; 37: 240–247.
- 35Eison TM, Ault BH, Jones DP, Chesney RW, Wyatt RJ. Post-streptococcal acute glomerulonephritis in children: clinical features and pathogenesis. Pediatr Nephrol 2011; 26: 165–180.
- 36Falconer AE, Carson R, Johnstone R, Bird P, Kehoe M, Calvert JE. Distinct IgG1 and IgG3 subclass responses to two streptococcal protein antigens in man: analysis of antibodies to streptolysin O and M protein using standardized subclass-specific enzyme-linked immunosorbent assays. Immunology 1993; 79: 89–94.
- 37Mortensen R, Nissen TN, Blauenfeldt T, Christensen JP, Andersen P, Dietrich J. Adaptive immunity against Streptococcus pyogenes in adults involves increased IFN-γ and IgG3 responses compared with children. J Immunol 2015; 195: 1657–1664.
- 38Raynes JM, Frost HRC, Williamson DA, et al. Serological evidence of immune priming by group A Streptococci in patients with acute rheumatic fever. Front Microbiol 2016; 7: 1119.
- 39Bright PD, Mayosi BM, Martin WJ. An immunological perspective on rheumatic heart disease pathogenesis: more questions than answers. Heart 2016; 102: 1527–1532.
- 40Salmond C, Crampton P, King P, Waldegrave C. NZiDep: a New Zealand index of socioeconomic deprivation for individuals. Soc Sci Med 2006; 62: 1474–1485.
- 41Du Clos TW, Mold C. C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity. Immunol Res 2004; 30: 261–277.
- 42Jones S, Moreland NJ, Zancolli M, et al. Development of an opsonophagocytic killing assay for group a streptococcus. Vaccine 2018; 36: 3756–3763.
- 43Chiarot E, Faralla C, Chiappini N, et al. Targeted amino acid substitutions impair streptolysin O toxicity and group A Streptococcus virulence. MBio 2013; 4: e00387-12.
- 44Jolliffe IT. Principal Component Analysis. Springer Series in Statistics. New York, NY: Springer, 1986.
10.1007/978-1-4757-1904-8 Google Scholar
- 45Tibshirani R. The lasso method for variable selection in the Cox model. Stat Med 1997; 16: 385–395.
10.1002/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3 CAS PubMed Web of Science® Google Scholar